Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 2
1972 1
1982 1
1983 1
2000 4
2001 5
2002 6
2003 8
2004 5
2005 8
2006 4
2007 11
2008 20
2009 18
2010 18
2011 16
2012 26
2013 18
2014 21
2015 38
2016 27
2017 33
2018 27
2019 27
2020 18
Text availability
Article attribute
Article type
Publication date

Search Results

324 results
Results by year
Filters applied: . Clear all
Page 1
Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M, Shousu K, Fujiki N, Sakurai M, Bonkobara M, Hwang CC, Coffey M, Noguchi S, Nemoto Y, Mizuno T. Igase M, et al. Vet Comp Oncol. 2019 Jun;17(2):184-193. doi: 10.1111/vco.12468. Epub 2019 Mar 13. Vet Comp Oncol. 2019. PMID: 30761736
However, anti-tumour effects of oncolytic therapy using reovirus against histiocytic sarcoma are unknown. Here, we showed that reovirus has oncolytic activity in canine histiocytic sarcoma cell lines in vitro and in vivo. ...In conclusion, oncolytic
However, anti-tumour effects of oncolytic therapy using reovirus against histiocytic sarcoma are unknown. Here, we showed that …
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review.
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently approved as the first oncolytic virus drug in the USA and Europe. ...Other oncolytic viruses that are closing in on drug approv …
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently a …
The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice.
Cai R, Meng G, Li Y, Wang W, Diao Y, Zhao S, Feng Q, Tang Y. Cai R, et al. Exp Biol Med (Maywood). 2019 Sep;244(12):983-991. doi: 10.1177/1535370219861928. Epub 2019 Jul 12. Exp Biol Med (Maywood). 2019. PMID: 31299861 Free PMC article.
As few studies have reported the efficacy of oncolytic activity and safety profile of avian reovirus, in our study, LDH assay, MTT assay, DAPI staining, and flow cytometry assay were performed to demonstrate the oncolytic effects of avian reovirus agai …
As few studies have reported the efficacy of oncolytic activity and safety profile of avian reovirus, in our study, LDH assay, …
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA. Samson A, et al. Sci Transl Med. 2018 Jan 3;10(422):eaam7577. doi: 10.1126/scitranslmed.aam7577. Sci Transl Med. 2018. PMID: 29298869 Free PMC article.
We show, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human Orthoreovirus (referred to herein as reovirus) leads to infection of tumor cells subsequently resected as part of standard clinical care, both in high-grade gliom …
We show, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human Orthoreovirus (referred to he …
Arming oncolytic reovirus with GM-CSF gene to enhance immunity.
Kemp V, van den Wollenberg DJM, Camps MGM, van Hall T, Kinderman P, Pronk-van Montfoort N, Hoeben RC. Kemp V, et al. Cancer Gene Ther. 2019 Sep;26(9-10):268-281. doi: 10.1038/s41417-018-0063-9. Epub 2018 Nov 23. Cancer Gene Ther. 2019. PMID: 30467340
Oncolytic reovirus administration has been well tolerated by cancer patients in clinical trials. However, its anti-cancer efficacy as a monotherapy remains to be augmented. ...The GM-CSF reoviruses represent a promising new agent for use in oncolytic virother
Oncolytic reovirus administration has been well tolerated by cancer patients in clinical trials. However, its anti-cancer effi
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. ...Oncolytic viral therapy for glioma remains promising and will undoubtedly impact the future of patient care....
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. .
Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins C, Simpson GR, Rogers W, Relph K, Harrington K, Melcher A, Roulstone V, Kyula J, Pandha H. Comins C, et al. Cancer Gene Ther. 2018 Jun;25(5-6):148-160. doi: 10.1038/s41417-018-0011-8. Epub 2018 May 3. Cancer Gene Ther. 2018. PMID: 29720674
There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. ...However, rapamycin attenuated viral replication if given prior or c …
There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene lahe …
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ. Berkeley RA, et al. Cancer Immunol Res. 2018 Oct;6(10):1161-1173. doi: 10.1158/2326-6066.CIR-18-0309. Epub 2018 Sep 12. Cancer Immunol Res. 2018. PMID: 30209061 Free article.
Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. ...However, we have found that human monocytes loaded with preformed reovirus-antibody complexes, in which the reovirus is full
Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. .
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S, Fukuhara H, Todo T. Taguchi S, et al. Jpn J Clin Oncol. 2019 Mar 1;49(3):201-209. doi: 10.1093/jjco/hyy170. Jpn J Clin Oncol. 2019. PMID: 30462296 Review.
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug approval: Pexa-Vec (pexastimogene devacirepvec), an oncolytic vaccinia virus, CG0070, an oncolytic adenovirus, and REOLYSIN (pel …
Other oncolytic viruses using different parental viruses have also been tested in Phase III clinical trials and are ready for drug ap …
Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery.
Kemp V, Dautzenberg IJC, Limpens RW, van den Wollenberg DJM, Hoeben RC. Kemp V, et al. Viruses. 2017 Sep 21;9(10):266. doi: 10.3390/v9100266. Viruses. 2017. PMID: 28934149 Free PMC article.
Mammalian reovirus is a double-stranded RNA virus that selectively infects and lyses transformed cells, making it an attractive oncolytic agent. ...Using UV-inactivated reovirus, we demonstrate that a productive reovirus infection facilitates the induc …
Mammalian reovirus is a double-stranded RNA virus that selectively infects and lyses transformed cells, making it an attractive on
324 results
Jump to page
Feedback